The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan.

Yasushi  Goto

Consulting or Advisory Role - Boston Biomedical; Lilly Japan

Speakers' Bureau - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical

Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)

Hiroshi  Nokihara

Honoraria - Boehringer Ingelheim; Lilly; Pfizer; Sanofi; Taiho Pharmaceutical

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)

Haruyasu  Murakami

Consulting or Advisory Role - Astellas Pharma; Clovis Oncology

Speakers' Bureau - Boston Biomedical; Chugai Pharma; Daiichi Sankyo; Nihonkayaku; Pfizer; Taiho Pharmaceutical

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)

Toshio  Shimizu

Research Funding - Astellas Pharma (Inst); Novartis (Inst); Verastem (Inst)

Takashi  Seto

Speakers' Bureau - AstraZeneca; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Fuji Pharma; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly Japan; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)

Andrew P.  Krivoshik

Employment - Astellas Pharma

Stock and Other Ownership Interests  - Abbott Diagnostics; Abbott Diagnostics (I); Abbvie; Abbvie (I); Johnson & Johnson; Johnson & Johnson (I); Merck; Merck (I)

Patents, Royalties, Other Intellectual Property - Abbott Diagnostics; Abbvie

Travel, Accommodations, Expenses - Astellas Pharma

Anne Therese  Keating

Employment - Astellas Pharma

Koichi  Uegaki

Employment - Astellas Pharma

Stock and Other Ownership Interests  - Astellas Pharma

Kentaro  Takeda

Employment - Astellas Pharma

Kanji  Komatsu

Employment - Astellas Pharma

Satoshi  Morita

Honoraria - Astellas Pharma

Consulting or Advisory Role - Astellas Pharma

Masahiro  Fukuoka

Honoraria - Astellas Pharma; Chugai Pharma

Kazuhiko  Nakagawa

Honoraria - Astellas Pharma; AstraZeneca; Chugai Pharma; Clovis Oncology; Novartis; Taiho Pharmaceutical

Speakers' Bureau - Astellas Pharma; AstraZeneca; Chugai Pharma; Clovis Oncology; Novartis; Taiho Pharmaceutical

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)